[A21-06] Entrectinib (NSCLC) - Addendum to Commission A20-75
Last updated 18.02.2021
Project no.:
A21-06
Commission:
Commission awarded on 13.01.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adults with ROS1-positive, advanced NSCLC not previously treated with ROS1 inhibitors
Result of dossier assessment:
Added benefit still not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-75 | Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.02.18 A G-BA decision was published.